Clinical trial NCT03089229: A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Official title: A Study to Evaluate the Efficacy and Safety of HAT01H, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Atopic Dermatitis
Eczema
Keywords: Topical Cream
Novel
Lead sponsor: Haus Bioceuticals
Sponsor class: INDUSTRY
First posted: 2017-03-24
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques. The current therapy of AD is reactive, where the flares are treated through symptomatic management with topical corticosteroids and calcineurin inhibitors. Given that these medications have long-term side-effects, and given the chronically relapsing immunopathogenic nature of AD, there is an imperative need for safer anti-inflammatory medications. Haus Bioceuticals (Haus) has developed a novel topical treatment for eczema/atopic dermatitis (AD) denoted HAT01H, and have demonstrated that HAT01H is safe and profoundly effective in the treatment of AD, controlling signs and symptoms in 85% of patients with AD. This study is aimed to further test the efficacy and safety of topical HAT01H in patients with moderate to severe atopic dermatitis.

Detailed description: This study is a 13 week (91 days) randomized, double-blind, in home use study among 30 male and female subjects with moderate to severe active atopic dermatitis (AD). The study will include subjects with ages 12 - 65 years old inclusive. Group assignments will be balanced by age and disease severity of AD. The study will consist of a 1 week washout period and 12 week treatment phase. During the treatment phase, subject will be provided one of the two test products to use twice daily on all lesions and non-lesional areas as instructed. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study. Measurements, expert visual assessments and self-assessments will be taken as described below. Safety and tolerability will be evaluated by incidence of AE's (defined per CTCAE), exacerbations, application site reactions/infections, and lab evals. There will also be consumption/compliance checks and dermatological evaluations at each visit.

Eligibility criteria: Inclusion Criteria:

* Moderate to severe atopic dermatitis as determined by PGA ≥ 3 and SCORAD \> 25
* Males and females, age 12 - 65 years old inclusive

Exclusion Criteria:

* Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 3 months.
* Currently or has been diagnosed or treated for cancer in the past 5 years.
* Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).
* Has a known hypersensitivity to any corticosteroid creams.
* Has any active infections or has used antibiotics in the past 7 days.
* Has any physical attributes or skin conditions that might interfere with clear visual assessments (i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne)
* Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.
* Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.
* Is an employee of the sponsor company or clinical testing site.
* Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.
* Is currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention).
* Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.

Primary outcomes:
measure: Change in Scoring of Atopic Dermatitis (SCORAD) score
timeFrame: Baseline to week 12
Secondary outcomes:
measure: Proportion of patients achieving a Physician's Global Assessment (PGA) score of 0 or 1
timeFrame: Baseline to week 12
measure: Incidence of treatment emergent Adverse Event
timeFrame: Baseline to week 12
Other outcomes:
Locations:
city: Bangalore
country: India
facility: Clinical Research Pvt Ltd
state: Karnataka
Study officials:
affiliation: Clinical
name: Mukta Sachdev, MD
role: PRINCIPAL_INVESTIGATOR
References: